Full Press Release Details
Medical Added to the Russell Microcap Index
inclusion in the appropriate growth and value style indexes
Mass., June 30, 2025 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular
Robotic System, announced that it was added as a member of the Russell Microcap Index. Microbot Medical's addition
will be effective today when the U.S. equity markets open.
in the Russell Microcap Index marks another important milestone for Microbot Medical. It reflects the strong execution
of our team and the momentum we have built, including our ongoing interaction with the FDA on our 510(k) submission for LIBERTY,"
commented Harel Gadot, Chairman, CEO and President. "As we continue to prepare for our anticipated Q3 launch, we are focused on
strengthening our operational and commercial infrastructure to ensure success. Being in the index, and the appropriate growth and value
style indexes, enhances our visibility at a pivotal time, and we look forward to continued progress in the months ahead."
annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market
capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion
in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
Russell's US indexes serve as the benchmark for about $10.6 trillion in assets as of the close of June 2024. Russell indexes are
part of FTSE Russell, the global index provider.
is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S.
Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and
improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use,
fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
information about Microbot Medical is available at http://www.microbotmedical.com.
to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements
that contain words such as "contemplates," "continues," "could," "forecasts," "intends,"
"may," "might," "possible," "potential," "predicts," "projects,"
"should," "would," "will," "believes," "plans," "anticipates,"
"expects," "estimates" and similar expressions) should also be considered to be forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,
including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition
to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular
Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant
510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting
from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements
of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran
and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical
can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and
Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims
any intent or obligation to update these forward-looking statements, except as required by law.